Skip to content

Search

Showing results for "aboriginal respiratory"

Healthy Skin and ARF Prevention

Our aim is for all kids to have healthy skin. We work with communities to reduce the burden of Strep A skin sores and sore throats to prevent rheumatic fever.

A community-based program to reduce acute rheumatic fever and rheumatic heart disease in northern Australia

In Australia’s north, Aboriginal peoples live with world-high rates of rheumatic heart disease (RHD) and its precursor, acute rheumatic fever (ARF); driven by social and environmental determinants of health. We undertook a program of work to strengthen RHD primordial and primary prevention using a model addressing six domains: housing and environmental support, community awareness and empowerment, health literacy, health and education service integration, health navigation and health provider education.

Epidemiology and determinants of cardiovascular disease in Indigenous populations

This Review describes the burden of cardiovascular disease across Indigenous populations and contextualizes the potential drivers and contributors to inequalities between Indigenous and non-Indigenous populations. The focus is on Indigenous populations across Aotearoa New Zealand, Australia, Canada and the USA, including Aboriginal and Torres Strait Islander, American Indian, Alaska Native, Canadian First Nations, Inuit, Métis, Māori, Native Hawaiian and Pacific Islander peoples.

Prevalence and subtyping of biofilms present in bronchoalveolar lavage from children with protracted bacterial bronchitis or non-cystic fibrosis bronchiectasis: a cross-sectional study

Lower airway biofilms are hypothesised to contribute to poor treatment outcomes among children with chronic lung disease; however, data are scarce.

Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021

Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.

Olfactory dysfunction at six months after coronavirus disease 2019 infection

This study aimed to assess olfactory dysfunction in patients at six months after confirmed coronavirus disease 2019 infection. Coronavirus disease 2019 positive patients were assessed six months following diagnosis. Patient data were recoded as part of the adapted International Severe Acute Respiratory and Emerging Infection Consortium Protocol. Olfactory dysfunction was assessed using the University of Pennsylvania Smell Identification Test.

Pre-term kids get green light to exercise

Parents of children born prematurely have expressed concerns about their child’s lung health when they exercise, with symptoms such as breathlessness.

Optimising a 6-plex tetanus-diphtheria-pertussis fluorescent bead-based immunoassay

Small volume assays are required for large-scale research studies and in particular paediatric trials, where multiple measures are required from a single sample. Fluorescent bead-based technology (Bioplex/Luminex) allows high through-put and simultaneous quantification of multiple analytes in a single test. This technology uses sets of microspheres, each with a unique spectral address that can be coated with a different antigen of interest.

The Impact of Modulator therapy from Early life on lung health trajectories in Cystic Fibrosis (TIME-CF)

Cystic fibrosis is an inherited condition that results in chronic lung disease. In recent years, a new type of medication called CFTR modulators has become available.

RHINO

RHINO researchers from The Kids' Wal-yan Respiratory Research Centre, will analyse ORIGINS data and turn it into meaningful respiratory and allergy outcome data that can be used by researchers around the world.